Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Immunological Reviews · 2024-11 · 328 (1) · 221-242
DOI: 10.1111/imr.13393 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 13.09.2024. Verfasst von Julia E Edgar und 1 weiteren Autor:innen. Beteiligte Einrichtung: The London School of Hygiene and Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibody-Dependent Enhancement, Immunoglobulin Fc Fragments, Receptors, IgG. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 290 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Advances in antibody technologies have resulted in the development of potent antibody‐based therapeutics with proven clinical efficacy against infectious diseases. Several monoclonal antibodies (mAbs), mainly against viruses such as SARS‐CoV‐2, HIV‐1, Ebola virus, influenza virus, and hepatitis B virus, are currently undergoing clinical testing or are already in use. Although these mAbs exhibit potent neutralizing activity that effectively blocks host cell infection, their antiviral activity results not only from Fab‐mediated virus neutralization, but also from the protective effector functions mediated through the interaction of their Fc domains with Fcγ receptors (FcγRs) on effector leukocytes. Fc‐FcγR interactions confer pleiotropic protective activities, including the clearance of opsonized virions and infected cells, as well as the induction of antiviral T‐cell responses. However, excessive or inappropriate activation of specific FcγR pathways can lead to disease enhancement and exacerbated pathology, as seen in the context of dengue virus infections. A comprehensive understanding of the diversity of Fc effector functions during infection has guided the development of engineered antiviral antibodies optimized for maximal effector activity, as well as the design of targeted therapeutic approaches to prevent antibody‐dependent enhancement of disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The London School of Hygiene and Tropical Medicine, London, UK.
- The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, New York, USA.
ORCID-Profile: Stylianos Bournazos
Förderung
- National Institute of Allergy and Infectious Diseases
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Institute
Zitieren
APA
Edgar, J. E., & Bournazos, S. (2024). Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement. Immunological Reviews, 328(1), 221-242. https://doi.org/10.1111/imr.13393
Vancouver
Edgar JE, Bournazos S. Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement. Immunological Reviews. 2024;328(1):221-242. doi:10.1111/imr.13393
BibTeX
@article{Edgar2024,
author = {Edgar, Julia E and Bournazos, Stylianos},
title = {Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement},
journal = {Immunological Reviews},
year = {2024},
volume = {328},
number = {1},
pages = {221--242},
doi = {10.1111/imr.13393}
}
EUVIMED